Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

20994 reported adverse events

Drugs of this class: BENRALIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 ASTHMA 3144
1 DYSPNOEA 2109
2 DEATH 1738
3 DRUG INEFFECTIVE 1580
4 PNEUMONIA 1218
5 COUGH 1111
6 PRODUCT DOSE OMISSION ISSUE 1078
7 HEADACHE 973
8 WHEEZING 791
9 FATIGUE 679
See all common reactions for Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

Drugs of the Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EOSINOPHIL COUNT ABNORMAL 62 0.0830
1 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 169 0.0828
2 EOSINOPHIL COUNT INCREASED 260 0.0312
3 ASTHMA 3144 0.0278
4 ASTHMATIC CRISIS 87 0.0238
5 NASAL POLYPS 104 0.0211
6 FULL BLOOD COUNT ABNORMAL 147 0.0139
7 SYMPTOM RECURRENCE 82 0.0137
8 WHEEZING 791 0.0133
9 OBSTRUCTIVE AIRWAYS DISORDER 140 0.0126
See all enriched reactions for Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]